The Abili-T trial is a randomized, double-blind, placebo-controlled research study of Tcelna in Secondary Progressive Multiple Sclerosis (SPMS) subjects. 180 subjects will be enrolled at approximately 30 leading clinical sites in the U.S. and Canada and will be treated and assessed for two years. Subjects who provide written, informal consent will complete screening assessments. Subjects meeting all the entry criteria will be randomized and provide blood to manufacture Tcelna. Subjects will receive 5 doses of study medication, either Tcelna or placebo, over 6 months each year of study. Numerous clinical and safety assessments will be conduct over the two year period.
See www.clinicaltrials.gov for more information, including a list of participating sites.